Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study

被引：1
|
作者：
Yang, Li [1 ]
Chen, Fangli [1 ]
Liang, Hong [2 ]
Bai, Yunsong [3 ]
Wu, Wenzhong [4 ]
Yan, Xiaojing [5 ]
Ren, Jinhai [6 ]
Li, Si [2 ]
Yu, Yang [2 ]
Tong, Laigen [4 ]
Pan, Deng [5 ]
Liu, Ligen [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Hematol,Hongqiao Int Inst Med, Shanghai, Peoples R China
[2] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Hematol, Changchun, Peoples R China
[4] Yixing Peoples Hosp, Yixing, Peoples R China
[5] China Med Univ, Hosp 1, Shenyang, Peoples R China
[6] Hebei Med Univ, Hosp 2, Dept Hematol, Shijiazhuang, Hebei, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184581
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia
    Qian, Jiejing
    Xu, Jieyu
    Hong, Qing
    Lou, Yinjun
    Mao, Liping
    Xu, Weilai
    Yang, Min
    Yu, Wenjuan
    Meng, Haitao
    Mai, Wenyuan
    Ye, Xiujing
    Zhu, Honghu
    Jin, Jie
    BLOOD, 2021, 138
  • [22] Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study
    Garcia-Manero, Guillermo
    Kazmierczak, Maciej
    Wierzbowska, Agnieszka
    Fong, Chun Yew
    Keng, Michael K.
    Ballinari, Gianluca
    Scarci, Francesco
    Ades, Lionel
    LEUKEMIA RESEARCH, 2024, 140
  • [23] COST-EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH AZACITIDINE IN UNFIT PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA IN CHINA
    Wu, Y.
    Xu, H.
    Zhao, X.
    Hong, G.
    Liu, J.
    Yang, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S132 - S132
  • [24] COSTS PER RESPONDER WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE IN UNFIT PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA IN CHINA
    Xu, H.
    Zhao, X.
    Mo, X.
    Zhao, J.
    Liu, J.
    Yang, Y.
    VALUE IN HEALTH, 2024, 27 (06) : S152 - S152
  • [25] Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
    Borate, Uma
    Huang, Ying
    Li Welkie, Rina
    Swords, Ronan T.
    Traer, Elie
    Stein, Eytan M.
    Lin, Tara L.
    Madanat, Yazan F.
    Patel, Prapti A.
    Collins, Robert H.
    Baer, Maria R.
    Duong, Vu H.
    Blum, William
    Arellano, Martha L.
    Stock, Wendy
    Odenike, Olatoyosi
    Redner, Robert L.
    Kovacsovics, Tibor J.
    Deininger, Michael W.
    Zeidner, Joshua F.
    Olin, Rebecca
    Smith, Catherine C.
    Foran, James M.
    Schiller, Gary J.
    Curran, Emily K.
    Koenig, Kristin L.
    Heerema, Nyla A.
    Chen, Timothy
    Martycz, Molly
    Stefanos, Mona
    Marcus, Sonja Gullen
    Druker, Brian J.
    Levine, Ross L.
    Burd, Amy
    Rossenber, Leohard
    Yocum, Ashley Owen
    Mims, Alice
    Byrd, John C.
    BLOOD, 2024, 144 : 4324 - 4326
  • [26] Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study
    Ma, Hongbing
    Du, Yiwen
    Li, Jianjun
    Rao, Jin
    Guo, Yong
    Yang, Yunfan
    Zhang, Duanzhong
    Wang, Jia
    Liao, Yi
    Gong, Yuping
    ANNALS OF HEMATOLOGY, 2024, : 5315 - 5323
  • [27] Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial
    Lane, Andrew A.
    Garcia, Jacqueline S.
    Raulston, Evangeline G.
    Garzon, Jada L.
    Galinsky, Ilene
    Baxter, Emilie W.
    Leonard, Rebecca
    DeAngelo, Daniel J.
    Luskin, Marlise R.
    Reilly, Christopher R.
    Stahl, Maximilian
    Stone, Richard M.
    Vedula, Rahul
    Wadleigh, Martha
    Winer, Eric S.
    Mughal, Tariq
    Brooks, Christopher
    Gupta, Ira V.
    Stevenson, Kristen E.
    Neuberg, Donna S.
    Ren, Siyang
    Konopleva, Marina Y.
    Stein, Anthony
    Pemmaraju, Naveen
    BLOOD, 2023, 142
  • [28] Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.
    You, Liangshun
    Liu, Yi
    Mai, Wenyuan
    Zhou, De
    Xie, Wanzhuo
    Mao, Liping
    Zhou, Xinping
    Tong, Hongyan
    Jin, Jie
    Meng, Haitao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Viale-t: A randomized, open-label, phase 3 study of venetoclax in combination with azacitidine after allogeneic stem cell transplantation in patients with acute myeloid leukemia
    Craddock, C.
    Platzbecker, U.
    Heuser, M.
    Pullarkat, V.
    Chaudhury, S.
    Wu, D.
    Addo, S.
    Chyla, B.
    Jiang, Q.
    Lee, P.
    Wolff, J. E.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 117 - 118
  • [30] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Konopleva, Marina
    Maiti, Abhishek
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Loghavi, Sanam
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Golez, Michelle
    Pierce, Sherry A.
    Nogueras Gonzalez, Graciela M.
    Ning, Jing
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2021, 138
12345